AMEV-Applied Molecular Evolution Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMEV-Applied Molecular Evolution

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who started this subject	12/17/2002 4:20:36 PM
From: nigel bates	Read Replies (1) of 164

SAN DIEGO--(BUSINESS WIRE)--Dec. 17, 2002--Applied Molecular Evolution, Inc. (AME) (Nasdaq: AMEV - News) today announced that it has achieved an initial milestone in its collaboration with Chiron Corporation to optimize a non-antibody biotherapeutic candidate. Financial terms of the milestone were not disclosed. "The efficiency of the AMEsystem(TM), including the ExpressAME(TM) mammalian cell expression system, enabled us to reach this goal in nine months," stated William D. Huse, M.D., Ph.D., President, Chief Executive Officer and Chairman of AME. "AME has again demonstrated that our protein engineering technology has the control and precision to deliver improvements in the function of protein therapeutic candidates as specified by our collaborators, this time for Chiron, a leading developer of biotherapeutics." ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next